Skip to content

Our Technology

Our History

Annual Report 2023

The Annual Report for 2023 was published on Thursday, April 18, 2024. This year it is also available in a summarized online format.

May 17, 2024

Interim Report Q1 2024

BioArctic AB published the company’s first quarter report for January – March 2024 on Friday, May 17, 2024, at 08:00 a.m. CET.

Audiocast with teleconference: at 09:30 CET the same day.

Our Therapeutic Areas of Expertise

Alzheimer’s disease

We are developing disease modifying treatments against Alzheimer’s disease. Lecanemab is an antibody targeting oligomers and protofibrils, the harmful forms of Aβ.

Parkinson’s disease

Due to the wide spread and severity of the disease, combined with a lack of effective pharmaceutical drugs, the need for new and effective treatments is significant.

Current treatments include drugs that slow down the disease development or relieve severe symptoms. BioArctic aims for targeting the cause of nerve cell damage.

Brain Transporter Technology

The blood-brain barrier controls the passage of substances between the bloodstream and the brain. It protects the brain, but can make it difficult to deliver drugs to the brain.

This is BioArctic

BioArctic is a Swedish research oriented biopharma company.  Based on our cutting-edge expertise in neurodegenerative disorders, we have built a broad and well-diversified project portfolio with the potential to improve the health of patients. The diversity of projects in various phases of development provides a solid basis for creating value for patients, their families, and society as a whole. This makes us an attractive company to both partners and investors.

Our progress in numbers

  • 20

    years of world leading research

  • 15

    research projects

  • 5

    cooperation principles


Investor contact

Oskar Bosson

VP, Head of IR & Communication